Searched for
TEVA GENERICS EUROPE
Sun Pharma shares rally 9% in two days after $12-bn Organon deal. Here's what Morgan Stanley, other brokerages saySun Pharmaceutical Industries' shares surged nearly 9% after announcing the $11.75 billion acquisition of Organon & Co., a global leader in...- Novo Nordisk sued in US for allegedly monopolizing diabetes drug VictozaDanish drugmaker Novo Nordisk faces a class action lawsuit in New York. The company is accused of using its patents to keep a monopoly on i...
- If Sun Pharma inspections come through, 2018 could be a turning point for Indian pharma: Amit Rajan, Prosfora Technology“We have to get our things in order for sterile manufacturing and Sun Pharma Halol plant is mostly on steriles.”
- Intas eyes Teva’s oncology, women’s health divisions in EuropeTeva, the world’s largest maker of generic drugs, plans to divest some assets including its global women’s health and European cancer and p...
- Teva appoints Dipankar Bhattacharjee as Prez, CEO Global Generic GroupAs President and CEO of Teva Generics Europe, Bhattacharjee has a proven track record of improving revenues and profitability, significantl...
- Intas buys Teva's UK & Ireland assets for $764 million to break into global top 20 generic players clubWith the acquisition of Teva’s products, sold through erstwhile Actavis’ operations, Intas is set to emerge as a top player in the UK gener...
- Aurobindo Pharma bids for Israeli generic company Teva's Irish & UK portfolio last week"Aurobindo Pharma is actively pursuing two more European acquisitions, each involving around $175 million -one based out of Spain and the o...
- Aurobindo, Intas in race for $1 billion buyout of Teva UK, submit binding offersIf successful, this would be Aurobindo's largest ever acquisition, surpassing its $132.5 mn purchase of US vitamin maker Natrol Inc in 2014.
- Torrent, Intas join fray for teva products in EuropeThe deal, said to be valued up to $1.5 billion, has seen the Hyderabadbased Aurobindo Pharma emerge as one of the front runners in the init...
- Cipla, Glenmark in race for hived-off Teva-Allergan generics in USSources indicated that Indian drug makers will be keen to buy the generic portfolio on offer, which could be valued at a minimum of $500 mi...
- Ex-Teva Frank Pieters to lead Cipla's European respiratory businessCipla, India's second-largest drug maker, has hired Teva's former vice-president Frank Pieters to spearhead its European respiratory busine...
- Natco, Mylan to appeal against New York district court verdictThe decision by the US court covers several patents for the chemical composition of Copaxone, methods of using the product and processes fo...
- Teva to buy Ratiopharm for nearly $5 bnIsrael's Teva has won the battle for German generic drugmaker Ratiopharm, paying an enterprise value of 3.63 billion euros to fix its weakn...
- Dr Reddy’s Lab embroiled in patent infringement row with AMRINYSE listed Dr Reddy’s Laboratories (DRL), India’s second largest company by revenue, is embroiled in a fresh patent infringement row with ...
- Teva to buy Barr Pharma for $7.5 bnIn the latest drug consolidation, Teva Pharmaceutical said on Friday it will buy rival generic drugmaker Barr Pharmaceuticals for nearly $7...
- Natco inks agreement with Mylan for CopaxoneHome grown major Natco Pharma today said it has signed a licence and supply agreement with US-based Mylan for the global sale of generic ve...
- Terms didn’t fit stringent acquisition criteria: TevaTeva Pharmaceutical Industries said on Sunday it stopped pursuing the purchase of the generics unit of German drugs and chemicals group Mer...
- Cos exit generics for core focusAs international generics drug markets reel under increasing pricing pressure and ever-rising competition, big pharma companies are selling...
- Merck buy may give Ranbaxy access to US, Europe marketsRanbaxy Labs has joined the race with global pharma companies such as Teva, Novartis and Sanofi-Aventis for acquiring the global generic dr...
- Matrix deal to trigger M&As in pharma secGlobal majors, Teva, Watson, Barr and Activis are also eyeing mid-sized and large Indian cos.
Load More
